MCK

McKesson
D

MCK

Arincen73/100B
1,085.80
USD
26.55
(2.51%)
Market Closed
Last updated: · Delayed 15 min
Fair value935.50Plus+16%589Price 1,085.801,311
Q3 FY2027 · Earnings report
EPS estimate 10.94Revenue estimate 113.63B
OverviewFinancialsForecastEarningsDividendsCompany

McKesson revenue 1995–2027

McKesson's revenue in Q2 FY2027, the three months to 30 September 2026, was 110.96B USD, up 7.6% on the same quarter a year before. McKesson's revenue over the last twelve months was 418.79B USD, up 8.2% on the twelve months before. In fiscal year 2026 it was 403.43B USD, up 12.4% on the year before.

Last updated 7 Nov 2026 · Next report 3 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 2026418.79B+8.19%15.37B4.70B
FY202631 Mar 2026403.43B+12.36%14.55B4.76B
FY202531 Mar 2025359.05B+16.22%12.49B3.30B
FY202431 Mar 2024308.95B+11.65%12.20B3.00B
FY202331 Mar 2023276.71B+4.83%11.87B3.56B
FY202231 Mar 2022263.97B+10.80%12.65B1.11B
FY202131 Mar 2021238.23B+3.11%11.58B-4.54B
FY202031 Mar 2020231.05B+7.81%11.40B900.00M
FY201931 Mar 2019214.32B+2.86%10.76B34.00M
FY201831 Mar 2018208.36B+4.95%10.39B67.00M
FY201731 Mar 2017198.53B+4.01%10.69B5.18B
FY201631 Mar 2016190.88B+6.61%10.94B2.26B
FY201531 Mar 2015179.05B+30.11%10.93B1.48B
FY201431 Mar 2014137.61B+12.38%8.04B1.26B
FY201331 Mar 2013122.46B-0.23%6.75B1.34B
FY201231 Mar 2012122.73B+9.50%6.43B1.40B
FY201131 Mar 2011112.08B+3.11%5.99B1.13B
FY201031 Mar 2010108.70B+1.94%5.68B1.26B
FY200931 Mar 2009106.63B+4.85%5.38B823.00M
FY200831 Mar 2008101.70B+9.39%5.00B990.00M
FY200731 Mar 200792.98B+5.60%4.34B963.00M
FY200631 Mar 200688.05B+9.36%3.78B738.00M
FY200531 Mar 200580.51B+15.84%3.45B-157.00M
FY200431 Mar 200469.51B+21.68%3.25B646.50M
FY200331 Mar 200357.12B+14.23%3.10B555.40M
FY200231 Mar 200250.01B+19.03%2.80B418.60M
FY200131 Mar 200142.01B+14.36%2.43B-48.30M
FY200031 Mar 200036.73B+20.91%2.52B723.70M
FY199931 Mar 199930.38B+45.67%2.86B84.90M
FY199831 Mar 199820.86B+61.85%1.61B154.90M
FY199731 Mar 199712.89B-6.05%1.11B133.90M
FY199631 Mar 199613.72B+4.00%1.22B135.40M
FY199531 Mar 199513.19B—1.16B404.50M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

McKesson revenue growth by segment

Q2 FY2027 against Q2 FY2026

North American Pharmaceutical91.36B
+5.6%
Oncology And Multispecialty14.98B
+24.4%
Medical-Surgical Solutions3.10B
+5.1%
Prescription Technology Solutions1.52B
+10.5%

McKesson revenue by segment over time

North American Pharmaceutical Oncology And Multispecialty Medical-Surgical Solutions Prescription Technology Solutions Other Technology Solutions Distribution Solutions U.S. Pharmaceutical International
Fiscal yearNorth American PharmaceuticalOncology And MultispecialtyMedical-Surgical SolutionsPrescription Technology SolutionsOtherTechnology SolutionsDistribution SolutionsU.S. PharmaceuticalInternational
FY2026336.65B 48.42B 11.51B +1.1%5.81B +11.3%1.04B — — — —
FY2025— — 11.39B +0.6%5.22B +9.4%— — — 327.72B +17.6%14.72B +4.2%
FY2024— — 11.31B +1.8%4.77B +8.7%— — — 278.74B +15.8%14.13B -31.4%
FY2023— — 11.11B -4.3%4.39B +13.5%— — — 240.62B +13.4%20.60B -43.3%
FY2022— — 11.61B +14.9%3.86B +33.7%— — — 212.15B +12.1%36.35B +1.1%
FY2021— — 10.10B +21.6%2.89B — — — 189.27B +3.2%35.97B
FY2020— — 8.31B +9.0%— — — — 183.34B +9.3%—
FY2019— — 7.62B — — — — 167.76B —
FY2018— — — — — 240.00M -90.8%208.12B +6.2%— —
FY2017— — — — — 2.61B -9.5%195.92B +4.2%— —

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about McKesson's revenue

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.